TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02851290

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Caudal block anesthesia
Description: After induction of general anesthesia, a caudal block will be performed using 0.75-1 mL/kg of 0.2% ropivacaine without epinephrine

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Dorsal penile nerve block anesthesia
Description: After induction of general anesthesia, a dorsal penile nerve block will be performed using 0.75-1 mL/kg of 0.2% ropivacaine without epinephrine
Study: NCT04145908

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: midline mesh reinforcement
Description: augmentation of midline closure by nonabsorbsble mesh

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: midline mesh reinforcement
Description: augmentation of midline closure by nonabsorbsble mesh
Study: NCT00600197

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: back school
Description: A kind of educational program for low back pain

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: back school
Description: A kind of educational program for low back pain
Study: NCT02368847

Intervention type: DEVICE
Group type: OTHER
Intervention: Diagnostic tests
Description: C Reactive Protein (CRP) measurement on capillary blood using a point-of-care test to determine C Reactive Protein level in the blood

Intervention type: DEVICE
Group type: OTHER
Intervention: Diagnostic tests
Description: Uricult dipslide: Easy-to-perform bacterial culture test for dectecting urinary tract infections in point of care settings
Study: NCT02354300

Intervention type: DEVICE
Intervention: TCD Ultrasound
Description: Transcranial doppler ultrasound monitoring will occur during flow diverter placement.
Study: NCT03537781

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Food labelling versus no food labelling
Description: Food labelling availability and satiety status

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Food labelling versus no food labelling
Description: Food labelling availability and satiety status

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Food labelling versus no food labelling
Description: Food labelling availability and satiety status

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Food labelling versus no food labelling
Description: Food labelling availability and satiety status
Study: NCT04224090

Intervention type: DIAGNOSTIC_TEST
Intervention: Echocardiographic assessment of coronary arteries origin and proximal course
Description: Echocardiographic assessment of CAA utilizing 4 specific echocardiographic acoustic windows: parasternal short-axis (PSAX), parasternal long-axis (PLAX), apical 4/5-chambers views.
Study: NCT01987622

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: The patients in this group will receive individualized acupuncture prescribed by a certified Korean Medicine Doctor (KMD) with at least three years of clinical experience. The acupuncture formulas will be determined based on the individual patient's symptoms and at the KMD's discretion. The acupuncture treatment will be applied one to three times a week for six weeks (a total of 12 sessions and an additional four sessions are allowed). Acupuncture will be manually stimulated at first, and then electrical stimulation will be allowed at the KMD's discretion. Retention time will be equal to or less than 20 minutes. Examples of acupuncture points to be used might include LI4, LI11, TE5, SI3, TE3, ST36, SP6, SP9, LR3, GB34, Gb39, BL40, BL57, EX-B2, and BL23.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Usual care
Description: Usual care consists of patient education for a healthier lifestyle, including diet, exercise, self-management of symptoms, and the use of other treatments as needed. Participants will receive a three-page leaflet of patient education material. Optional regular physical therapies, including interferential current therapy (ICT) and local heat application, will be provided only for the control group at the participants' request . Physical therapy will be provided one to three times a week for six weeks (a total of 12 sessions and an additional four sessions are allowed). All kinds of conservative interventions for lumbar spinal stenosis, including analgesics and non-study physical treatments,will be allowed. However, surgical treatments, non-study acupuncture, or herbal medicine will not be allowed.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Usual care consists of patient education for a healthier lifestyle, including diet, exercise, self-management of symptoms, and the use of other treatments as needed. Participants will receive a three-page leaflet of patient education material. Optional regular physical therapies, including interferential current therapy (ICT) and local heat application, will be provided only for the control group at the participants' request . Physical therapy will be provided one to three times a week for six weeks (a total of 12 sessions and an additional four sessions are allowed). All kinds of conservative interventions for lumbar spinal stenosis, including analgesics and non-study physical treatments,will be allowed. However, surgical treatments, non-study acupuncture, or herbal medicine will not be allowed.
Study: NCT03992287

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Hydrolysed Red Ginseng Extract
Description: 10 ml/day, 2.4g/day for 12 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo for 12 weeks
Study: NCT05053698

Intervention type: OTHER
Intervention: Aqueous flare measurement
Description: Aqueous flare was measured preoperatively and postoperatively with a laser flare-cell meter (LFCM ; Kowa FM-500, Kowa Company Ltd, Tokyo, Japan).

Intervention type: OTHER
Intervention: Aqueous flare measurement
Description: Aqueous flare was measured preoperatively and postoperatively with a laser flare-cell meter (LFCM ; Kowa FM-500, Kowa Company Ltd, Tokyo, Japan).

Intervention type: OTHER
Intervention: Aqueous flare measurement
Description: Aqueous flare was measured preoperatively and postoperatively with a laser flare-cell meter (LFCM ; Kowa FM-500, Kowa Company Ltd, Tokyo, Japan).

Intervention type: OTHER
Intervention: Aqueous flare measurement
Description: Aqueous flare was measured preoperatively and postoperatively with a laser flare-cell meter (LFCM ; Kowa FM-500, Kowa Company Ltd, Tokyo, Japan).
Study: NCT01948505

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous acetaminophen

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for IV acetaminophen
Study: NCT02829671

Intervention type: OTHER
Group type: OTHER
Intervention: Clinical and biological assessment
Description: Blood sample, clinical assessment with questionnaires
Study: NCT03997747

Intervention type: OTHER
Intervention: cytology specimen
Description: Biopsy and Genetic: DNA analysis;Genetic: RNA analysis;Genetic: microarray analysis; Genetic: mutation analysis; Genetic: polymorphism analysis
Study: NCT01477437

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Teens Taking Charge: Managing Hemophilia Online- Online self-management intervention
Description: The content will be delivered on a password-protected website, as part of the About Kids Health interface developed and maintained at the Hospital for Sick Children, Toronto, Canada. The website has been developed as eight discrete educational modules for adolescents. Each module takes approximately 30 to 45 minutes to complete. Content has been written and reviewed by experts from comprehensive hemophilia care clinics across Canada (physicians, nurses, physiotherapists and social workers) and edited by a medical writer to ensure that it is written at the suggested grade 6 reading level for patient education materials. Content has been written in English and will be translated into French prior to program launch. The format is geared towards adolescents and includes narratives with video components and interactive illustrations. In addition, each module will have quiz questions with real-time feedback to promote interactivity and knowledge retention.
Study: NCT01977261

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Opening-wedge HTO
Description: Opening-wedge high tibial osteotomy fixated with a Puddu plate
Study: NCT00405457

Intervention type: DRUG
Group type: OTHER
Intervention: Restasis, Optive Tears
Description: Restasis and Optive Tears use twice daily more frequently if needed
Study: NCT04477421

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: FS-SMILE
Description: Femtosecond small incision lenticule extraction

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: S-LASIK
Description: Femtosecond laser Insitu keratomileusis
Study: NCT03160287

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivaltional interviews and infrequent motivational text messages
Description: A self-management intervention will integrate use of mobile technology to prompt older adults to be physically active, provides ongoing monitoring of the amount of their physical activity and includes self-efficacy enhancements is a novel non-pharmacological intervention both for prevention and treatment of sleep deficiency in persons with OA
Study: NCT00390195

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RAD001 (everolimus)
Description: Arm 1: 2.5, 5, 7.5 or 10 mg of RAD001 daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RAD001 (everolimus)
Description: Arm 2: 20, 30, 50 or 70 mg of RAD001 daily
Study: NCT01991821

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APD421

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02476955

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARQ 092 + carboplatin + paclitaxel (Closed)
Description: Subjects will receive ARQ 092 orally at dose levels specified for their respective dose cohorts plus carboplatin (AUC6, intravenously, Day 1) plus paclitaxel (175 mg/m2, intravenously, Day 1) on a 21-day schedule.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARQ 092 + paclitaxel (Closed)
Description: ARQ 092 will be administered orally at 200 mg twice a day (BID) weekly (Cohort 1P) of a 28-day cycle in combination with an intravenous (IV) infusion of paclitaxel (80 mg/m2). ARQ 092 will be administered once a week on Day 1, Day 8, Day 15, and Day 22 of each 28-day cycle; paclitaxel will be administered once a week on Day 1, Day 8, and Day 15 for three consecutive weeks followed by one week off of each 28-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARQ 092 + anastrozole
Description: ARQ 092 will be administered orally at 150 mg QD, 5 days on/9 days of a 28 day cycle in combination with anastrozole which will be administered orally at 1 mg QD continuously.
Study: NCT02459223

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Nutritional biscuits and khichadi
Description: Nutritional biscuits and Khichadi.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Khichadi
Description: Khichadi.
Study: NCT02410993

Intervention type: PROCEDURE
Intervention: CABG surgery
Study: NCT01544959

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fentanyl
Description: Use of esmolol and metoprolol compared to use of fentanyl for hemodynamic control during general anesthesia. At induction, fentanyl (2 mcg/kg) is replaced by esmolol (1 mg/kg). During the case, with a standardised anesthesia, response to surgical stimulation will be medicated either by fentanyl (50 mcg aliquot) or metropolol (2.5 mg), for a maximum of 6 doses. After this, fentanyl will be given unblindly.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: beta-blocker (esmolol, metropolol)
Description: esmolol is used at induction and lopressor during surgery instead of fentanyl in response to surgical stimulation.
Study: NCT04172805

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: anlotinib and toripalimab
Description: Anlotinib 12mg orally per day, two weeks on , one week off; 240 mg of toripalimab (fixed dose) every three weeks. Repeat every three weeks. Patients with disease control (CR + PR + SD) and tolerable adverse reactions continued to take medication until the researchers concluded that patients were not suitable to continue medication or the efficacy evaluation was disease progression (PD). No other antineoplastic treatment can be given during the treatment.
Study: NCT02382718

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: FAST fish mCyp c 1
Description: Subcutaneous immunotherapy

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subcutaneous immunotherapy
Study: NCT04671433

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Genetic: AAV5-hRKp.RPGR
Description: Bilateral, sub-retinal administration of AAV5-hRKp.RPGR - immediate treatment group

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Genetic: AAV5-hRKp.RPGR
Description: Bilateral, sub-retinal administration of AAV5-hRKp.RPGR - immediate treatment group

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Genetic: AAV5-hRKp.RPGR
Description: No intervention - deferred treatment group (Bilateral, sub-retinal administration of AAV5-hRKp.RPGR to be administered in the follow-up study)
Study: NCT01304121

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bioactive glass (SP53P4)
Description: Commercial resorbable bone graft substitute (Vioxid Ltd)
Study: NCT01140334

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Voucher Reinforcement
Description: Patients in this condition will be able to earn a voucher for each week that they have attended all scheduled psychiatric sessions. These sessions may include individual therapy appointments, group therapy appointments, or psychiatrist appointments. Each voucher will be worth $25, and can be exchanged for goods and services that will be purchased by a research assistant. The maximum amount of voucher earnings over the study is $300.
Study: NCT02864342

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Arm 1: BreatheMate device with application
Description: The service known as 'BreatheMate' is a patient support tool that monitors daily Symbicort inhaler use. The BreatheMate service includes a bluetooth monitoring device that is attached to subjects' Symbicort pMDI inhaler which automatically detects and logs their maintenance medication use. Subjects will receive audio-visual daily reminders (beeps and flashes) on the BreatheMate Bluetooth device. The bluetooth device transmits this data to a cellular phone that is provided to all subjects in the study. Subjects in the intervention group will also receive audio-visual alerts (beeps, flashes) from the bluetooth device to take their medication.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Arm 2: BreatheMate device without application
Description: The service known as 'BreatheMate' is a patient support tool that monitors daily Symbicort inhaler use. The BreatheMate service includes a bluetooth monitoring device that is attached to subjects' Symbicort pMDI inhaler which automatically detects and logs their maintenance medication use. The functionality of audio-visual daily reminders (beeps and flashes) is deactivated for this control group.~The BreatheMate service also includes a cellular phone that will display whether the Bluetooth monitoring device is paired and communicating with the cellular phone. The Bluetooth device will transmit data regarding medication usage to the cellular phone.
Study: NCT01140334

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Control
Description: Patients assigned to this condition will be treated at ATS for psychological problems. They will be scheduled to participate in individual therapy sessions with a psychiatrist and with their substance abuse counselor. They will also be referred to attend group therapy one time per week. No voucher incentive will be offered in this condition.
Study: NCT04176341

Intervention type: OTHER
Group type: OTHER
Intervention: a systematic proposal for non pharmacological interventions targeting the subject's empowerment among slackline, mindfulness, adapted physical activity, self-hypnosis, and Qi Gong
Description: chronic pain patient consulting in Grenoble Alps University Hospital, and Hospital Mutualist Group who will one non pharmacological intervention between slackline, mindfulness, adapted physical activity, self-hypnosis, Qi Gong during 6 to 8 weeks.
Study: NCT02993887

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Resourcefulness Training
Description: This intervention will include a one time face to face instruction on Resourcefulness Training that entails 8 self-help and help-seeking skills plus viewing short video vignettes of caregivers describing application of the resourcefulness skills. In addition, participants will use daily journaling to describe application of the resourcefulness skills in their daily caregiving with their technology-dependent child.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Mindfulness
Description: The mindfulness intervention will include the use of an app daily via Stop, Think, Breathe.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness
Description: The mindfulness intervention will include the use of an app daily via Stop, Think, Breathe.
Study: NCT01859793

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sitagliptin
Description: 100 mg pill, administered once/day orally

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo in appearance given once/day orally
Study: NCT04557098

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Teclistamab
Description: Teclistamab will be administered SC.
Study: NCT02143037

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: prize contingency management for attending treatment

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: usual care

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: usual care
Study: NCT03116464

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telemental Health Family Intervention
Description: Approximately 12-16 session family intervention that will include the following specific strategies, the implementation of which will be tailored by clinicians to the specific interpersonal deficits identified in an assessment: (1) psychoeducation on dementia, (2) communication and problem solving skills, (3) safety building skills, (4) relationship satisfaction enhancement skills, (5) meaning making (i.e. collaboratively identifying the personal significance of events), (6) identification of core patterns from dyad relationship history, (7) techniques to shift emotional responses, (8) techniques to increase emotional attunement, and (9) techniques to increase attunement to care-recipient needs
Study: NCT03988582

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: EBV-specific T-cells
Description: During each cycle, patients will receive intravenous (IV) EBV-CTLs at a dose of 1×106 CD3+ cells/kg on Days 1, 8, and 15, followed by a 2-week observation period.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: EBV-specific T-cells
Description: During each cycle, patients will receive intravenous (IV) EBV-CTLs at a dose of 1×106 CD3+ cells/kg on Days 1, 8, and 15, followed by a 2-week observation period.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: EBV-specific T-cells
Description: During each cycle, patients will receive intravenous (IV) EBV-CTLs at a dose of 1×106 CD3+ cells/kg on Days 1, 8, and 15, followed by a 2-week observation period.
Study: NCT04323982

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: new surgical procedure
Description: （ACCC + I / A + PCCC + TA+ A-vit) or （ACCC + I / A + PCCC + IOL + TA + A-vit）

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: traditional surgical procedure
Description: （ACCC + I / A + PCCC + A-vit) or （ACCC + I / A + PCCC + IOL + A-vit）
Study: NCT00735111

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Karnofsky Performance Status Score
Description: Karnofsky Performance Status scores will be independently completed by both the patient and their health-care provider at each routine clinic visit.
Study: NCT01977261

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Closing-wedge HTO
Description: Closing-wedge high tibial osteotomy fixated with two staples
Study: NCT00186914

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Marrow stromal cell infusion
Description: This is a pilot study of infusions of ex vivo expanded, gene marked donor bone marrow stromal cells following allogeneic bone marrow transplantation. The study is a within patient dose escalation safety evaluation. It is believed that this patient population may benefit from these donor stromal cell infusions.~As the stromal cells will be obtained from the original stem cell donor, no conditioning is required.~Patients will receive two infusions of mesenchymal cells (MSC) approximately 14 to 21 days apart unless there is unacceptable toxicity after the first infusion. The first dose of cells to be given will be 1x10\^6 MSC/kg and the second dose of cells will be 5x10\^6 MSC/kg. The patients will be followed for approximately 28 days following the second infusion for any toxicity. Only after all six patients have safely completed both infusions will we consider 5 x 10\^6 MSC/kg a safe dose of allogeneic mesenchymal stem cells for infusion.
Study: NCT02127047

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitagliptin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitagliptin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exercise
Study: NCT01773512

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Description: All patients will be using rosuvastatin 40 mg
Study: NCT00192296

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MEDI-528 0.3 mg/kg
Description: MEDI-528 (0.3 mg/kg) administered as a single, intravenous (IV) dose
Study: NCT04661241

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Automatic DRT/VIM target-recognition method using MR-SISET and ML approaches
Description: The proposed sequence (\<15 minutes) will be added as a supplementary sequence only for the preoperative imaging for subjects who agree to participate: a 3D multi-echo GRE sequence will be performed during a preoperative MR imaging, using the following parameters: field of view = 220x170x75 mm3, matrix = 176x136x60, 1.25-mm isotropic resolution, flip angle = 22 degrees, TR = 92 ms, 20 TEs = 1.90 - 45.98 ms with echo spacing of 2.32 ms, bandwidth = 840 Hz/pixel.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Routine clinical MRI protocol
Description: MRI will be performed using 3T scanner (Skyra, Siemens, Erlangen, Germany). All patients will undergo preoperative MRI of the brain including routine clinical MRI protocol (T1-/T2-weighted and diffusion imaging) under general anesthesia to reduce movement artifacts.
Study: NCT00192296

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MEDI-528 1 mg/kg
Description: MEDI-528 (1 mg/kg) administered as a single, IV dose